

David B Weiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3464616/publications.pdf>

Version: 2024-02-01

52
papers

4,512
citations

186265

28
h-index

175258

52
g-index

55
all docs

55
docs citations

55
times ranked

6579
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA vaccines: ready for prime time?. <i>Nature Reviews Genetics</i> , 2008, 9, 776-788.	16.3	882
2	Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2015, 386, 2078-2088.	13.7	529
3	Immunogenicity of a DNA vaccine candidate for COVID-19. <i>Nature Communications</i> , 2020, 11, 2601.	12.8	514
4	Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, e35.	27.0	244
5	Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 1013-1022.	9.1	235
6	A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. <i>Science Translational Medicine</i> , 2015, 7, 301ra132.	12.4	214
7	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. <i>EClinicalMedicine</i> , 2021, 31, 100689.	7.1	206
8	Modulating the immune response to genetic immunization. <i>FASEB Journal</i> , 1998, 12, 1611-1626.	0.5	154
9	Alarmin IL-33 Acts as an Immunoadjuvant to Enhance Antigen-Specific Tumor Immunity. <i>Cancer Research</i> , 2014, 74, 1789-1800.	0.9	129
10	DNA vaccines: prime time is now. <i>Current Opinion in Immunology</i> , 2020, 65, 21-27.	5.5	123
11	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. <i>Nature Communications</i> , 2021, 12, 346.	12.8	107
12	Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 110-124.	7.0	102
13	Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. <i>Journal of Infectious Diseases</i> , 2019, 220, 400-410.	4.0	91
14	A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge. <i>Cancer Immunology Research</i> , 2019, 7, 174-182.	3.4	75
15	Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. <i>Vaccine</i> , 2009, 27, 431-440.	3.8	73
16	Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. <i>Scientific Reports</i> , 2015, 5, 12616.	3.3	65
17	Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. <i>Current Opinion in Virology</i> , 2011, 1, 233-240.	5.4	57
18	Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185HER2Antibody. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1993, 9, 448-454.	2.9	47

#	ARTICLE	IF	CITATIONS
19	Regulation of synovial cell growth: Coexpression of transforming growth factor β 2 and basic fibroblast growth factor by cultured synovial cells. <i>Arthritis and Rheumatism</i> , 1992, 35, 1296-1303.	6.7	43
20	Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. <i>Molecular Therapy</i> , 2018, 26, 435-445.	8.2	39
21	In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. <i>Cell Reports</i> , 2018, 25, 1982-1993.e4.	6.4	38
22	A METHOD TO COLLECT AND PROCESS SKIN BIOPSIES FOR CELL CULTURE FROM FREE-RANGING GRAY WHALES (<i>ESCHRICHTIUS ROBUSTUS</i>). <i>Marine Mammal Science</i> , 1988, 4, 1-12.	1.8	37
23	DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. <i>JCI Insight</i> , 2019, 4, .	5.0	36
24	Protective immunity by an engineered DNA vaccine for Mayaro virus. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007042.	3.0	35
25	Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. <i>Vaccine</i> , 2015, 33, 4313-4320.	3.8	33
26	Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 276-294.	7.0	32
27	An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of <i>Clostridium difficile</i> Induces Protective Antibody Responses <i>In Vivo</i> . <i>Infection and Immunity</i> , 2014, 82, 4080-4091.	2.2	31
28	Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16025.	4.4	30
29	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. <i>Advanced Science</i> , 2020, 7, 1902802.	11.2	30
30	In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1 neutralizing activity. <i>Journal of Clinical Investigation</i> , 2020, 130, 827-837.	8.2	30
31	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. <i>Frontiers in Medical Technology</i> , 2020, 2, 571030.	2.5	29
32	Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models. <i>Molecular Therapy</i> , 2019, 27, 314-325.	8.2	27
33	Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. <i>Microbes and Infection</i> , 2018, 20, 676-684.	1.9	25
34	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .	5.0	25
35	A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote <i>In Vivo</i> Tumor Control. <i>Cancer Immunology Research</i> , 2020, 8, 1354-1364.	3.4	20
36	RNA-Based Vaccination: Sending a Strong Message. <i>Molecular Therapy</i> , 2013, 21, 506-508.	8.2	16

#	ARTICLE	IF	CITATIONS
37	Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig. <i>EBioMedicine</i> , 2018, 35, 97-105.	6.1	15
38	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. <i>IScience</i> , 2021, 24, 102699.	4.1	15
39	Safety, bioavailability, and pharmacokinetics of VGX-1027: A novel oral anti-inflammatory drug in healthy human subjects. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 91-101.	1.6	12
40	Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein-Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth. <i>Vaccines</i> , 2019, 7, 44.	4.4	11
41	Incorporation of a Novel CD4+ Helper Epitope Identified from <i>Aquifex aeolicus</i> Enhances Humoral Responses Induced by DNA and Protein Vaccinations. <i>IScience</i> , 2020, 23, 101399.	4.1	11
42	A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 278-287.	4.4	7
43	In vivo DNA-launched bispecific T cell engager targeting IL-13R α 2 controls tumor growth in an animal model of glioblastoma multiforme. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 289-301.	4.4	6
44	Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from <i>Plasmodium</i> Infection in a Murine Model. <i>Infection and Immunity</i> , 2021, 89, e0072820.	2.2	5
45	Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18) Tj ETQq1 1 0.784314 rgB / <i>Oncology</i> , 2017, 35, 6073-6073.	1.6	5
46	Diagnosis and prediction of pediatric HIV-1 infection and AIDS: Current status. <i>Journal of Clinical Laboratory Analysis</i> , 1994, 8, 309-314.	2.1	4
47	DNA-Encoded Glutamine Synthetase Enzyme as Ammonia-Lowering Therapeutic for Hyperammonemia. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 379-391.	3.6	2
48	DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 218-229.	4.4	2
49	Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. <i>Nature Communications</i> , 2022, 13, 695.	12.8	2
50	Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses. <i>JCI Insight</i> , 2022, 7, .	5.0	2
51	Nanoparticle Vaccines: In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity (Adv.) Tj ETQq1 1 0.7843 14 rgBT / <i>Advances in Protein Chemistry and Biophysics</i> , 2022, 93, 1-24.	1.6	1
52	Improved Durability to SARS-CoV-2 Vaccine Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1. <i>Journal of Immunology</i> , 2022, 209, 118-127.	0.8	1